Nurix Therapeutics (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company focused on harnessing the body’s natural protein regulation systems to discover and develop small-molecule therapeutics. The company leverages its proprietary targeted protein modulation (TPM) platform, including targeted protein degradation (TPD) and molecular glue approaches, to address unmet medical needs in oncology and immunology. Nurix’s pipeline includes multiple clinical-stage candidates designed to selectively degrade or modulate disease-causing proteins, offering a potential new class of precision medicines.
Among Nurix’s lead programs is NX-2127, a Bruton’s tyrosine kinase (BTK) degrader in clinical trials for B-cell malignancies, and NX-5948, a degrader targeting BTK and related kinases for immune-mediated diseases. These programs are underpinned by the company’s UbiLearn® research platform, which identifies novel E3 ligases, and the UbiFocus® lead optimization engine, which refines small molecules for enhanced efficacy and selectivity. Nurix also pursues earlier-stage discovery efforts in additional oncology targets, immuno-oncology combinations, and inflammatory disorders.
Nurix maintains strategic collaborations with leading pharmaceutical companies to expand the reach and application of its protein modulation technology. Notably, it has partnered with Gilead Sciences, Bristol-Myers Squibb, and Janssen Pharmaceuticals to co-develop degrader and molecular glue candidates across multiple therapeutic areas. These alliances provide Nurix with access to complementary expertise, resources and global development networks, accelerating the translation of its novel chemistry platforms into clinical assets.
Founded in 2015 and headquartered in San Francisco, California, Nurix Therapeutics is led by President and Chief Executive Officer Gary B. Evans, Ph.D., who brings extensive experience in drug discovery and biotechnology leadership. The company’s management team consists of seasoned professionals in research and development, regulatory strategy and commercialization. As Nurix advances its portfolio through clinical milestones and new partnerships, it aims to establish targeted protein modulation as a transformative approach for treating complex diseases worldwide.
